COVINGTON, Ky., Aug. 18, 2026 /PRNewswire/ — NeuroQuant ® PET has received FDA 510(k) clearance (K261916) for PET. NeuroQuant PET ® aids physicians in the evaluation of patient pathologies and the clinical interpretation of PET performed for the assessment of cognitive impairment and other neurological conditions.
Doctor-created Livi addresses a long-overlooked need in post-sex intimate health, available exclusively at MyLivi.com.
The ZEISS CLINIC 360 all-in-one browser-based software solution aggregates clinical data at scale and powers advanced analytics for streamlined ophthalmic workflows, providing clinicians with more time for personalizing patient care.
Touting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers, Enveda plans to test the asset in people stopping GLP-1 treatment.
MIT researchers’ approach, which uses naturally occurring sugars as antifreeze, could make it easier for hospitals to deploy this type of cancer treatment.
Empatica’s platform enables continuous tracking of symptoms such as bradykinesia, dyskinesia and sleep quality.
The approval covers smartSedLine monitor availability in applicable European markets.
WUXI, China, Aug. 19, 2026 /PRNewswire/ — NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy and Fast Track designations to NORROY’s 68Ga-NYM096, a potential radiopharmaceutical imaging agent targeting carbonic anhydrase Ⅸ (CAⅨ) for PET imaging of clear cell renal cell carcinoma (ccRCC).
BOSTON, Aug. 19, 2026 /PRNewswire/ — Empatica, a leader in digital biomarker development and clinical-grade wearable technology, today announced that the Empatica Health Monitoring Platform for Parkinson’s has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).